Trial Profile
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Jun 2022
Price :
$35
*
At a glance
- Drugs Sipuleucel-T (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Acronyms PROCEED
- Sponsors Dendreon Corporation
- 24 Jul 2021 Results of assessing the analysis of circulating immune biomarkers among racial subgroups of Black and white men with metastatic castration-resistant prostate cancer treated with sipuleucel-t, published in the Journal of the National Cancer Institute.
- 22 Jun 2021 Planned number of patients changed from 1500 to 1900.
- 12 Mar 2020 According to an Dendreon Pharmaceuticals media release, data from this study were published online in Prostate Cancer and Prostatic Diseases (PCAN), a peer-reviewed Nature Research journal.